Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib

Phase: 3

Status: Ongoing

Details

ASPEN – A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis

Sponsor: Insmed

NCT04594369

Sponsors

HOPE Cancer Center

Hope Cancer Center

Contact

Contact UT Clinical
Scroll to Top